secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001193125-26-043741
Event type: leadership
Sentiment:  negative
Materiality: 0.90
Item codes: 5.02, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto CEO departs; authorized shares increased to 500M; outstanding shares jump to 43.6M after preferred conversion
--------------------------------------------------------------------------------

- CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.
- Shareholders approve increase in authorized common shares from 300M to 500M, plus Cayman Islands redomestication.
- Automatic conversion of Series C Preferred yields ~42M new shares; total outstanding rises from ~1.6M to ~43.6M.
- Shareholders also approve 2026 Equity Incentive Plan and Employee Stock Purchase Plan.
- Separation agreement for Schambye includes lump-sum base salary continuation, pro-rated bonus, and full equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526043741/0001193125-26-043741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526043741/glto-20260206.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-043741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer